首页 | 本学科首页   官方微博 | 高级检索  
     


Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir,pegylated interferon plus ribavirin combination therapy
Authors:Yuki Tahata  Naoki Hiramatsu  Tsugiko Oze  Ayako Urabe  Naoki Morishita  Ryoko Yamada  Takayuki Yakushijin  Atsushi Hosui  Masahide Oshita  Akira Kaneko  Hideki Hagiwara  Eiji Mita  Toshifumi Ito  Yukinori Yamada  Masami Inada  Kazuhiro Katayama  Shinji Tamura  Yasuharu Imai  Hayato Hikita  Ryotaro Sakamori  Yuichi Yoshida  Tomohide Tatsumi  Norio Hayashi  Tetsuo Takehara
Affiliation:1. Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan;2. Osaka Rosai Hospital, Sakai, Osaka, Japan;3. Osaka Police Hospital, Osaka, Osaka, Japan;4. NTT West Osaka Hospital, Osaka, Osaka, Japan;5. Kansai Rousai Hospital, Amagasaki, Hyogo, Japan;6. National Hospital Organization, Osaka National Hospital, Osaka, Osaka, Japan;7. Japan Community Health Care Organization Osaka Hospital, Osaka, Osaka, Japan;8. Kaizuka City Hospital, Kaizuka, Osaka, Japan;9. Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan;10. Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka, Japan;11. Minoh City Hospital, Minoh, Osaka, Japan;12. Ikeda Municipal Hospital, Ikeda, Osaka, Japan
Abstract:
Keywords:chronic hepatitis C  interleukin 28B  ribavirin dose  simeprevir  sustained virologic response
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号